{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05224141\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["MK-7684A"]],"indication":"first-line extensive-stage small cell lung cancer","name":"KEYVIBE-008","nct_id":"NCT05224141","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keyvibe-008-nct05224141. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation (FDC) of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684A) every 3 weeks (Q3W) via intravenous (IV) infusion, in combination with 100 mg/m\\^2 etoposide, and platinum (Area Under the Curve \\[AUC\\] 5 mg/mL/min carboplatin or 75 mg/m\\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of MK-7684A (200 mg vibostolimab/200 mg pembrolizumab FDC) Q3W via IV infusion, until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1.","label":"Pembrolizumab/Vibostolimab","type":"EXPERIMENTAL"},{"description":"Participants will receive 4 cycles (each cycle is 3 weeks) of 1200 mg atezolizumab Q3W via IV infusion, in combination with 100 mg/m\\^2 etoposide and platinum (AUC 5 mg/mL/min carboplatin or 75 mg/m\\^2 cisplatin) chemotherapy Q3W for a total of approximately 12 weeks. This will be followed by additional cycles of atezolizumab (1200mg atezolizumab) Q3W via IV infusion until any of the conditions for discontinuation are met. To maintain the blinding, saline placebo will be administered on cycle 1 day 1 and then Q3W as needed beyond cycle 1.","label":"Atezolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-06-07","type":"ESTIMATED"},"conditions":["Small Cell Lung Carcinoma"],"enrollment":{"count":460,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab/Vibostolimab Co-Formulation","otherNames":["MK-7684A"],"type":"BIOLOGICAL"},{"name":"Saline placebo","otherNames":[],"type":"DRUG"},{"name":"Etoposide","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":["PLATINOL-AQ®"],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["TECENTRIQ®"],"type":"BIOLOGICAL"},{"name":"Carboplatin","otherNames":["PARAPLATIN®"],"type":"DRUG"}],"last_update":"2025-07-08","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-06-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 25 months"}],"references":[{"citation":"Sands J, Lu S, Aerts JG, Reck M, Navarro A, Shentzer Kutiel T, Peled N, Casarini I, Kerr SJ, Takahashi T, Bilici A, Cheng Y, Wang M, Lee SY, Lowczak A, Mazieres J, Hu H, Wu J, Aggarwal H, El-Osta H, Paz-Ares L. Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer. Target Oncol. 2026 Oct 20. doi: 10.1007/s11523-026-01237-w. Online ahead of print.","pmid":"42900351","type":"DERIVED"},{"citation":"Shapira-Frommer R, Niu J, Perets R, Peters S, Shouse G, Lugowska I, Garassino MC, Sands J, Keenan T, Zhao B, Healy J, Ahn MJ. The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. Future Oncol. 2024;20(27):1983-1991. doi: 10.1080/14796694.2024.2343272. Epub 2024 Sep 4.","pmid":"39230120","type":"DERIVED"}],"start_date":{"date":"2022-03-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","url":"https://clinicaltrials.gov/study/NCT05224141"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keyvibe-008-nct05224141"}